Induction of Interferon-Stimulated Genes Correlates with Reduced Growth of Influenza A Virus in Lungs after RIG-I Agonist Treatment of Ferrets.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
24 08 2022
Historique:
pubmed: 3 8 2022
medline: 27 8 2022
entrez: 2 8 2022
Statut: ppublish

Résumé

Intracellular RIG-I receptors represent key innate sensors of RNA virus infection, and RIG-I activation results in the induction of hundreds of host effector genes, including interferon-stimulated genes (ISGs). Synthetic RNA agonists targeting RIG-I have shown promise as antivirals against a broad spectrum of viruses, including influenza A virus (IAV), in both

Identifiants

pubmed: 35916513
doi: 10.1128/jvi.00559-22
pmc: PMC9400473
doi:

Substances chimiques

Antiviral Agents 0
Interferons 9008-11-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0055922

Références

Curr Protoc Microbiol. 2006 Dec;Chapter 15:Unit 15G.1
pubmed: 18770580
Immunity. 2009 Jul 17;31(1):25-34
pubmed: 19576794
Mol Ther. 2017 Sep 6;25(9):2093-2103
pubmed: 28760668
PLoS One. 2012;7(2):e27517
pubmed: 22359533
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
J Antimicrob Chemother. 2014 Sep;69(9):2458-69
pubmed: 24840623
J Virol. 2009 Apr;83(8):3843-51
pubmed: 19193792
Vaccine. 2017 Jan 3;35(1):46-52
pubmed: 27899226
Nat Methods. 2015 Feb;12(2):115-21
pubmed: 25633503
J Virol Methods. 2014 Sep 1;205:38-52
pubmed: 24797460
Curr Opin Virol. 2011 Dec;1(6):519-25
pubmed: 22328912
J Virol. 2015 Aug;89(15):8011-25
pubmed: 26018150
J Virol. 2018 Jan 30;92(4):
pubmed: 29187546
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Infect Immun. 1979 Sep;25(3):992-7
pubmed: 500197
J Virol. 2014 Apr;88(8):4180-94
pubmed: 24478443
PLoS Pathog. 2013;9(4):e1003298
pubmed: 23633948
J Vis Exp. 2015 Mar 19;(97):
pubmed: 25867050
Genome Biol. 2014;15(12):550
pubmed: 25516281
Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12067-72
pubmed: 19574455
Front Microbiol. 2016 Mar 23;7:326
pubmed: 27047455
Virology. 2015 May;479-480:110-21
pubmed: 25749629
Nat Biotechnol. 2020 Mar;38(3):276-278
pubmed: 32055031
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
J Virol. 2010 Sep;84(17):8369-88
pubmed: 20534862
Vaccine. 2000 Jan 31;18(14):1412-8
pubmed: 10618539
Viruses. 2017 Dec 07;9(12):
pubmed: 29215570
Mol Ther. 2011 Mar;19(3):602-11
pubmed: 20959813
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
J Clin Virol. 2015 Jul;68:43-8
pubmed: 26071334
Nat Med. 2004 Aug;10(8):871-5
pubmed: 15247913
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10172-7
pubmed: 20498074
Genome Biol. 2010;11(10):R106
pubmed: 20979621
Nature. 2014 Oct 16;514(7522):372-375
pubmed: 25119032
J Virol. 2004 Apr;78(7):3572-7
pubmed: 15016880
J Virol. 2013 Jul;87(14):7793-804
pubmed: 23698296
Nat Immunol. 2004 Jul;5(7):730-7
pubmed: 15208624
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
PLoS One. 2011 Mar 14;6(3):e17618
pubmed: 21423798
Front Immunol. 2018 Jun 20;9:1379
pubmed: 29973930
J Virol. 2020 Nov 23;94(24):
pubmed: 32967961
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Exp Med. 2022 Jan 3;219(1):
pubmed: 34757384
Science. 2006 Nov 10;314(5801):994-7
pubmed: 17038590
Antiviral Res. 2020 Apr;176:104751
pubmed: 32088248
Immunity. 2011 May 27;34(5):680-92
pubmed: 21616437
Curr Opin Virol. 2015 Jun;12:1-6
pubmed: 25638592
Expert Opin Drug Discov. 2018 Dec;13(12):1131-1139
pubmed: 30362841
Nature. 2006 Oct 5;443(7111):578-81
pubmed: 17006449
J Immunol. 2014 Nov 1;193(9):4643-53
pubmed: 25267977
Mol Ther Nucleic Acids. 2022 Mar 8;27:1225-1234
pubmed: 35186439
J Virol. 1985 Sep;55(3):517-20
pubmed: 4020957
Virol J. 2010 May 21;7:102
pubmed: 20492658

Auteurs

Lara S U Schwab (LSU)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbournegrid.1008.9, Victoria, Australia.
Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.

Sarah L Londrigan (SL)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbournegrid.1008.9, Victoria, Australia.

Andrew G Brooks (AG)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbournegrid.1008.9, Victoria, Australia.

Aeron C Hurt (AC)

WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute for Infection and Immunity, Victoria, Australia.

Anshupa Sahu (A)

Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
Institute of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Bonn, Germany.

Yi-Mo Deng (YM)

WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute for Infection and Immunity, Victoria, Australia.

Jean Moselen (J)

WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute for Infection and Immunity, Victoria, Australia.

Christoph Coch (C)

Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.

Thomas Zillinger (T)

Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.

Gunther Hartmann (G)

Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.

Patrick C Reading (PC)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbournegrid.1008.9, Victoria, Australia.
WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute for Infection and Immunity, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH